Psilocybin, MDMA, DMT, and LSD analogs are being studied in FDA-approved trials for depression, PTSD, adjustment disorder, and anxiety-related disorders. As regulatory approval approaches, clinicians need clarity on how these treatments fit within existing mental health systems. Providers may hesitate due to questions about whether psychedelic care replaces other therapies, competes with medication management, or disrupts established treatment relationships. A provider education gap exists around trial expectations and patient eligibility information. Psychedelic trials can function as specialty interventions within collaborative care models, supporting continuity rather than pulling patients away from primary providers.
Read at Psychology Today
Unable to calculate read time
Collection
[
|
...
]